Levron Medical has formally exited stealth mode to advance development of what it calls a new category of heart failure treatment.
The Israel-based cardiovascular technology company announced the move after completing initial first-in-human testing and securing a recent funding round. The company is now preparing to begin a clinical validation study at Sheba Medical Center in collaboration with ARC, the hospital’s innovation arm.
Levron’s $2.2 million funding round was led by Shoni Health Ventures. Additional investors include MedTech entrepreneur Dr. Shimon Eckhouse, Alon MedTech Ventures, and the Technion – Israel Institute of Technology. The financing will help support regulatory progress and clinical validation efforts, according to the company.
First-in-Human Data Drives Next Phase
The company’s proprietary Cardio-Respiratory Physiology Assist (CRPA) technology is designed to support patients with both reduced and preserved ejection fraction heart failure. According to Levron leadership, early clinical evidence demonstrated improvements in respiratory function and hemodynamic markers in treated patients.
Chief executive Amir Ronen described the approach as a shift in how clinicians may eventually support heart failure, stating that the company is leveraging a mechanism historically considered counterintuitive. Ronen added that the technology aims to combine the clinical impact of traditional medical devices with faster development cycles and lower cost, offering potential advantages for scalability and deployment.
The upcoming clinical study at Sheba Medical Center will be led by Prof. Elad Maor, Director of the Heart Failure Institute, as part of a collaboration with the facility’s Leviev Heart Center.
With funding secured and clinical development underway, Levron now moves toward validating whether its CRPA technology can offer a new therapeutic pathway for millions of patients living with heart failure worldwide.
Recent Funding Activity
Healthcare sector has seen a flurry of activity in recent months. Recently, US-based Sorcero announced the closing of a $42.5 million Series B funding round for its artificial intelligence (AI) platform. University of California, Berkeley (UC Berkley) spin-off Voio, a frontier AI lab dedicated to healthcare, emerged from stealth with $8.6 million in seed funding.
In October, another Israeli health technology startup, CustoMED, raised $6 million in seed funding to advance its AI powered 3D printing applications in orthopedic surgery.
Apart from AI, companies have also raised funds for disease-specific therapies. This month, AAVantgarde raised $141 million in Series B financing for its clinical programs targeting Stargardt disease and Usher syndrome type 1B, both inherited retinal diseases (IRDs). Modulight closed a $12 million seed funding round for treating neurological disorders like chronic pain and epilepsy. Danish biopharmaceutical BOOST Pharma announced a SEK 34 million ($3.55 million) investment from Sound Bioventures. The funds will be used to develop its stem cell-based therapy for osteogenesis imperfecta (OI), also known as brittle bone disease.
In October, PACE (Pathways to Antimicrobial Clinical Efficacy), one of the UK’s largest public-private initiatives, launched a £6 million ($8 million) funding round. In July, Swedish biotech, Pila Pharma, secured SEK 20 million ($1.8 million) to explore its oral TRPV1 inhibitor as a new obesity treatment option.
Other funding included myTomorrows raising $29 million investment from a US-based healthcare-focused investment firm, Avego, to connect patients with pre-approval treatments.
